![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Wyeth |
Information provided by: | Wyeth |
ClinicalTrials.gov Identifier: | NCT00234338 |
The purpose of this study is to estimate the local and systemic tolerability of Prevenar in children ages 2 to 5 years old in usual care settings.
Condition |
Pneumococcal Disease |
ChemIDplus related topics: | Heptavalent pneumococcal conjugate vaccine Pneumococcal Vaccines |
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | Prospective Post-Marketing Surveillance Study of Prevenar in High-Risk Children Aged 2 to 5 Years |
Ages Eligible for Study: | 2 Years to 5 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion criteria:
Study ID Numbers: | 101850 |
First Received: | October 4, 2005 |
Last Updated: | December 7, 2007 |
ClinicalTrials.gov Identifier: | NCT00234338 |
Health Authority: | Germany: Paul-Ehrlich-Institut |
|
![]() |